For the first-line treatment of small cell lung cancer, the international multi-center phase III clinical study of Fuhong Hanlius' PD-1 inhibitor, Slulimumab, reached the primary endpoint of OS

The main purpose of this study is to study the effectiveness and safety of slulimumab combined with chemotherapy in ES-SCLC patients who have not received previous treatment

Professor Cheng Ying, the main investigator of the NCT04063163 study, the director of the Jilin Provincial Cancer Center, the director of the Jilin Provincial Lung Cancer Diagnosis and Treatment Center, and the director of the Malignant Tumor Clinical Research Integrated Diagnosis and Treatment Center of Jilin Provincial Tumor Hospital, said : "I am very excited to see the widespread use of slulimumab.

Professor Wang Jie from the Chinese Academy of Medical Sciences Tumor Hospital, IDMC chairman of the NCT04063163 study , said : “SCLC is a type of lung cancer with strong aggressiveness and poor prognosis.

Another IDMC member, Professor Giorgio Scagliotti from the Medical Oncology Center of the University of Turin, Italy , said : “The global clinical options for SCLC are very limited, especially anti-PD-1 monoclonal antibody-related treatment options.

Mr.